AC Immune has 'remarkable' Alzheimer's vaccine data. Just don't ask to see them
AC Immune announced it has “remarkable,” “unprecedented” results on an Alzheimer’s vaccine. You’re just not allowed to see the data.
On Thursday, the J&J-partnered Swiss biotech said that its vaccine had generated “high” levels of antibodies against tau, a tangled protein commonly implicated in Alzheimer’s, in every patient in their Phase I/II trial for the neurodegenerative disease. The stock $ACIU instantly doubled in pre-market trading, rising from $7.30 to $14.70, and briefly making AC Immune once again a $1 billion company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.